Wall Street analysts predict that Cambrex Co. (NYSE:CBM) will announce earnings of $0.52 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Cambrex’s earnings, with estimates ranging from $0.49 to $0.53. Cambrex posted earnings per share of $0.74 during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.7%. The company is scheduled to issue its next earnings results on Thursday, August 1st.
On average, analysts expect that Cambrex will report full year earnings of $2.04 per share for the current year, with EPS estimates ranging from $2.02 to $2.08. For the next fiscal year, analysts expect that the company will report earnings of $1.99 per share, with EPS estimates ranging from $1.95 to $2.06. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Cambrex.
Cambrex (NYSE:CBM) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.10. The business had revenue of $159.46 million during the quarter, compared to analysts’ expectations of $159.71 million. Cambrex had a return on equity of 12.25% and a net margin of 14.35%. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.72 earnings per share.
A number of brokerages have recently commented on CBM. Robert W. Baird cut Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price target for the company. in a research note on Friday, May 3rd. They noted that the move was a valuation call. First Analysis downgraded Cambrex from a “strong-buy” rating to an “outperform” rating and increased their price target for the stock from $45.00 to $55.00 in a report on Tuesday, May 7th. ValuEngine upgraded Cambrex from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Finally, Zacks Investment Research downgraded Cambrex from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $47.40.
Several institutional investors have recently bought and sold shares of CBM. William Blair Investment Management LLC grew its stake in Cambrex by 2.9% in the 1st quarter. William Blair Investment Management LLC now owns 2,659,481 shares of the biotechnology company’s stock valued at $103,321,000 after buying an additional 75,662 shares in the last quarter. Clearbridge Investments LLC grew its stake in Cambrex by 0.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,337,800 shares of the biotechnology company’s stock valued at $51,974,000 after buying an additional 3,589 shares in the last quarter. Lazard Asset Management LLC grew its stake in Cambrex by 16.8% in the 1st quarter. Lazard Asset Management LLC now owns 924,844 shares of the biotechnology company’s stock valued at $35,930,000 after buying an additional 133,133 shares in the last quarter. American Capital Management Inc. grew its stake in Cambrex by 14.3% in the 1st quarter. American Capital Management Inc. now owns 764,238 shares of the biotechnology company’s stock valued at $29,691,000 after buying an additional 95,441 shares in the last quarter. Finally, Granite Investment Partners LLC grew its stake in Cambrex by 54.5% in the 1st quarter. Granite Investment Partners LLC now owns 445,764 shares of the biotechnology company’s stock valued at $17,318,000 after buying an additional 157,298 shares in the last quarter.
NYSE CBM opened at $43.80 on Friday. The business’s fifty day simple moving average is $44.91. The company has a quick ratio of 2.01, a current ratio of 2.96 and a debt-to-equity ratio of 0.79. Cambrex has a fifty-two week low of $33.80 and a fifty-two week high of $69.43. The company has a market capitalization of $1.46 billion, a PE ratio of 15.81, a PEG ratio of 3.39 and a beta of 2.35.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Recommended Story: What is Forex?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.